Join Jason Rockhill, MD, PhD and John Thompson, MD as they present their multidisciplinary expertise on a range of cases pertaining to advanced disease melanoma.
Treatment of advanced melanoma has entered a new era with the approval of novel immunotherapeutic and targeted agents. Two additional targeted agents—MEK inhibitor trametinib and BRAF inhibitor dabrafenib—have received approval for patients with documented V600 mutation of BRAF based on survival benefits in randomized trials. A new class of upcoming agents targeted against the programmed death -1 (PD-1) receptor (lambrolizumab and nivolumab) also demonstrated durable responses in patients with advanced melanoma, which may further change the landscape of this rapidly evolving field.
Evidence from follow-up studies of vemurafenib and ipilimumab shed light on their use in different clinical settings, drug resistance mechanisms, and side effects management. Research also focused on the sequence and combination of novel drugs. A recent FDA approval was granted to the combination of dabrafenib and trametinib based on improved progression-free survival compared to monotherapy.
In advanced disease, clinicians need to know the prognostic markers prior to deciding on a treatment for the patient. With the advent of targeted therapy, mutation testing has become a critical component in the routine work-up of advanced disease. Management of adverse events and response to therapy may be different than with traditional chemotherapy. These differences should be discussed with patients prior to beginning therapy with immune-oncology agents.
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including Lymphoma: Mantle Cell, Lymphoma: CLL/SLL, Chronic Phase CML, Multiple Myeloma, Breast Cancer: Adjuvant Systemic Therapy, Breast Cancer: Advanced Disease, Lung Cancer: Biomarker Driven Advanced Disease, Lung Cancer: Locally Advanced NSCLC: Stage IIIA Management, Metastatic Colorectal Cancer, Prostate Cancer: Castrate Resistant, Melanoma, and Kidney Cancer. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (June 2014 until June 2015).
The NCCN Guidelines are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
Monday, October 20, 2014 2:00 PM - 3:00 PMEastern Time
NCCN Meetings Department
World Time Zone MapSee when meeting occurs in other time zonesWorld Time Zone Map
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300